Journal of Infectious Diseases & Therapy
Open Access

Review Article

Global Epidemiology on Colistin Resistant Acinetobacter baumannii

¹Department of Infectious Diseases, Faculty of Medicine, Erciyes University, Kayseri, Turkey

²Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

*Corresponding Author:

Salman Shaheer Ahmed
Department of Infectious Diseases
Faculty of Medicine, Erciyes University
38039-Kayseri, Turkey
Tel: +90 531 381 9526
E-mail: biosheffield@gmail.com

Received date: June 27, 2016; Accepted date: July 05, 2016; Published date: July 07, 2016

Citation: Ahmed SS, Alp E, Hopman J, Voss A (2016) Global Epidemiology on Colistin Resistant Acinetobacter baumannii. J Infect Dis Ther 4:287. doi:10.4172/2332-0877.1000287

Copyright: © 2016 Ahmed SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

While colistin remains a last resort agent to treat multi-drug resistant Acinetobacter baumannii, resistance to colistin has been reported throughout the world. The resistance has been attributed to mutations in lipid A biosynthesis genes and point mutation in PmrAB-two component response regulator and sensor kinase system. The emergence of plasmid mediated colistin resistance (mcr-1), in multidrug-resistant enterobacteriaceae raised concerns, though mcr-1 has not yet been reported in A. baumannii. Lately, colistin resistance has been attributed to efflux pumps belonging to RND family. While various reports of emergence of colistin resistance are associated with previous treatment with colistin, other reports concern patients without any prior therapy.

Keywords